Literature DB >> 10190725

Spatial distribution of tissue inhibitor of metalloproteinase-1 mRNA in chronic liver disease.

Y Yata1, T Takahara, K Furui, L P Zhang, B Jin, A Watanabe.   

Abstract

BACKGROUND/AIMS: Tissue inhibitor of metalloproteinase-1, a specific inhibitor of matrix metalloproteinases, plays an important role in the pathogenesis of fibrosis and tumor progression. However, the precise expression of tissue inhibitor of metalloproteinase-1 messenger RNA in human hepatic fibrosis has not yet been defined. We investigated the spatial distribution of tissue inhibitor of metalloproteinase-1 messenger RNA in chronic human liver disease.
METHODS: Northern and in situ hybridization of probes to tissue inhibitor of metalloproteinase-1 messenger RNA were performed in specimens from 16 surgically resected human livers. Immunohistochemical staining of sections for tissue inhibitor of metalloproteinase-1 and immunoelectron microscopy were also performed.
RESULTS: Northern hybridization demonstrated that expression of tissue inhibitor of metalloproteinase-1 messenger RNA was increased 3.9-fold in mild chronic hepatitis, 6.8-fold in moderate chronic hepatitis, and 6.4-fold in cirrhosis, compared with control liver. In situ hybridization showed the expression of tissue inhibitor of metalloproteinase-1 messenger RNA in spindle-shaped cells in the fibrous septa and lobules in chronic hepatitis and cirrhosis; these cells were immunohistochemically positive for a-smooth muscle actin. Immunoelectron microscopy revealed localization of tissue inhibitor of metalloproteinase-1 in between fibers, to the rough endoplasmic reticula of stellate cells located in the lobules and periportal areas, and to fibroblasts in the fibrous septa. These results indicate that tissue inhibitor of metalloproteinase-1 was produced mainly by stellate cells in the specimens of chronic liver diseases.
CONCLUSIONS: Expression of tissue inhibitor of metalloproteinase-1 messenger RNA is increased in hepatic fibrosis and stellate cells are involved primarily in its expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190725     DOI: 10.1016/s0168-8278(99)80101-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Expression of tissue inhibitor of matrix metalloproteinases-1 during aging in rat liver.

Authors:  Yu-Mei Zhang; Xiang-Mei Chen; Di Wu; Suo-Zhu Shi; Zhong Yin; Rui Ding; Yang Lü
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

2.  Transcriptional regulation of human alpha1(I) procollagen gene in dermal fibroblasts.

Authors:  Chun-Fang Gao; Hao Wang; Ai-Hua Wang; Wei-Dong Wan; Yan-Aan Wu; Xian-Tao Kong
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

3.  Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.

Authors:  Bin-Bin Zhang; Wei-Min Cai; Hong-Lei Weng; Zhong-Rong Hu; Jun Lu; Min Zheng; Rong-Hua Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 4.  Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives.

Authors:  Ryota Masuzaki; Tatsuo Kanda; Reina Sasaki; Naoki Matsumoto; Masahiro Ogawa; Shunichi Matsuoka; Seth J Karp; Mitsuhiko Moriyama
Journal:  Int J Mol Sci       Date:  2020-07-11       Impact factor: 5.923

5.  Role of host genetics in fibrosis.

Authors:  Georgina L Hold; Paraskevi Untiveros; Karin A Saunders; Emad M El-Omar
Journal:  Fibrogenesis Tissue Repair       Date:  2009-12-04

6.  Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease.

Authors:  Timo Rath; Lisa Hage; Marion Kügler; Katrin Menendez Menendez; Reinhart Zachoval; Lutz Naehrlich; Richard Schulz; Martin Roderfeld; Elke Roeb
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.